** Shares of medtech co Zynex ZYXI.O fall 14.7% to $5.97 aftermarket
** Reports Q4 net revenue of $46 mln compared to $47.3 mln a year ago
** Says that the revenue shortfall was due to slower-than-normal payments from certain payers as well as a temporary suspension of payments from healthcare service provider Tricare
** Co says TriCare represents about 20%-25% of annual revenue
** Says due to the temporary payment suspension, co is cutting jobs by about 15%
** The staff reduction along with other expense reductions will result in savings of about $35 mln annually — ZYXI
** Co expects Q1 2025 net revenue of at least $30 mln vs estimates of $53.5 mln — LSEG data
** Stock has fallen 26.5% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.